Return to the top


2 June 2017

PRX302 (topsalysin) clinical trial opens at Imperial College NHS Trust

A clinical trial evaluating a promising new treatment for localised clinically significant prostate cancer has opened at Imperial College Healthcare NHS Trust. Professor is the global Chief Investigator of this study running in sites across the UK and the USA looking to demonstrate whether PRX302 (topsalysin) can effectively treat prostate cancer with minimal side-effects.